Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial

Article Immunology

A Retrospective Study of Ipilimumab Plus Nivolumab in Anti-PD-L1/PD-1 Refractory Merkel Cell Carcinoma

Sophia Z. Shalhout et al.

JOURNAL OF IMMUNOTHERAPY (2022)

Article Oncology

Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma

Sean McBride et al.

Summary: The study compared the efficacy of nivolumab alone versus nivolumab plus SBRT in treating patients with metastatic HNSCC, and found that the addition of SBRT did not improve treatment response in unselected patients.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma

Valerie Glutsch et al.

Summary: In a small retrospective study conducted at three different academic sites in Germany, it was observed that patients with avelumab-refractory metastatic MCC had a high response rate and durable responses to subsequent combined immunotherapy with IPI/NIVO. The data suggests promising activity of second- or third-line PD-1 plus CTLA-4 blockade in patients with anti-PD-L1-refractory MCC.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)

Add to Collection

Article Medicine, General & Internal

First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial

Paul Baas et al.

Summary: Nivolumab plus ipilimumab demonstrated significant improvement in overall survival compared to standard chemotherapy for unresectable malignant pleural mesothelioma. This first-in-class treatment regimen has been approved for previously untreated patients in the USA and showed promising outcomes with manageable adverse events.

LANCET (2021)

Add to Collection

Article Oncology

Response durability after cessation of immune checkpoint inhibitors in patients with metastatic Merkel cell carcinoma: a retrospective multicenter DeCOG study

H. M. Stege et al.

Summary: The study found that MCC patients are at a higher risk of relapse after discontinuation of ICI compared to melanoma patients. Re-induction of ICI is a feasible option for tumor progression, with initial BOR to ICI therapy potentially predicting successful re-induction.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)

Add to Collection

Article Oncology

Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial

Nasser K. Altorki et al.

Summary: The combination of neoadjuvant durvalumab and stereotactic body radiotherapy in early-stage NSCLC patients shows a high major pathological response rate and is well tolerated, suggesting its potential in treatment, although it comes with certain adverse events.

LANCET ONCOLOGY (2021)

Add to Collection

Article Oncology

Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma

Paul Nghiem et al.

Summary: In this study, the use of pembrolizumab in Merkel cell carcinoma patients showed a 58% overall response rate and a 39.1% 3-year progression-free survival rate. Patients with specific baseline factors and completion of 2 years of treatment were associated with better response and longer survival. Some patients experiencing disease progression or relapse following response had extended survival with salvage therapies including chemotherapies and immunotherapies.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Add to Collection

Article Oncology

First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study

Sandra P. D'Angelo et al.

Summary: In patients with mMCC, first-line treatment with avelumab led to responses in 40% and durable responses in 30%, being associated with a low rate of grade 3/4 treatment-related adverse events.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Add to Collection

Article Oncology